hypophysectomized rats and the pattern of its efficacy(body weight gain and growth plate width) was dose-dependent.

[PE1-26] [10/18/2002 (Fri) 13:30 - 16:30 / Hall C]

Preparation of mono-PEGylated interferon alpha-2a and its properties

Jo YeongWoo[O], Park BeomSoo, Kim WonGeun, Jeon HyunKyu, Choi YunKyu, Lee SungHee, Kim WonBae, Na DongHee, Lee KangChoon, Choi EungChil

Research Laboratories, Dong-A Pharm. Co., Ltd.
College of Pharmacy, Sungkyunkwan University
College of Pharmacy, Seoul National University

Recombinant interferon alpha is widely used for the treatment of diseases including chronic hepatitis C. However, it has drawbacks such as relatively short serum half-life and rapid clearance like other therapeutic proteins. Using PEGylation which is one of the well-established methods to fulfill the requirements of a long-lasting form of protein, we prepared mono-PEG modified interferon alpha-2a in which polyethylene glycol moiety was covalently attached to the amino groups of interferon alpha-2a. Monopegylated interferon alpha-2a was purified from conjugation reaction mixture employing only one chromatography step. The purity was over 95% by SDS-PAGE and high performance liquid chromatography. Physicochemical and biological characterization on pegylated interferon alpha-2a was also performed. N-terminal amino acid sequencing, analysis on the amino acid composition and circular dichroism spectrometry indicated that pegylated interferon alpha maintained the same primary and secondary structure as the unmodified interferon alpha protein. We also identified that it showed the intrinsic antiviral activity of interferon alpha by cytopathic effect (CPE) assay.

[PE1-27] [10/18/2002 (Fri) 13:30 - 16:30 / Hall C]

A comparative study of pharmacopoeia between South Korea and North Korea(I)

Jang Seung Jae, Kang Chan Soon, Choi Bo Kyung, Kim Hye Soo, Choi Myoengsin[O], Hong Chong Hui, Ko Yong Seok, Kim Sang Hyun

Korea Food and Drug Administration

With the Sunshine policy, exchange of goods and cultures inter Koreas is broaden and expectancy of reunification is getting higher.
Especially, medical supplies and medicines is one of the biggest parts in the exchanges.
So, need for preparing new medical administration system for reunification is needed.
We are going to compare inter Koreas drug administration system in medical services.
In this year, we started with the comparing pharmacopoeia between South and North Korea. Two pharmacopoeias have been developed in different direction and have many differences in the nomenclature and structure of that.
In this thesis, we compared General notices, General rules for preparations and crude drugs, Monographs, General tests, Processes & Apparatus.

Poster Presentations - Field E2. Pharmacokinetics

[PE2-1] [10/18/2002 (Fri) 13:30 - 16:30 / Hall C]

Determination of enalapril in human blood by high-performance liquid chromatography mass

spectrometer.

Chang Dong-jin°, Shim Chang-Koo, Chung Suk-Jae

Department of Pharmaceutics, College of Pharmacy, Seoul National University

Enalapril, a prodrug, is the ethyl ester of a long-acting angiotensin converting enzyme inhibitor, enalaprilat. Because enalapril does not contain any appreciable chromophore, detection of the drug in a complex matrix (e.g., biological fluids) has been problematic with conventional detection systems in high-performance liquid chromatography (HPLC). As a result, determination of enalapril level in blood samples has been typically carried out using HPLC-MS/MS in the literature. Since availability of HPLC-MS/MS has been significantly limited, we studied the feasibility of using HPLC-MS, a more widely equipped instrument, for the determination of the drug in human blood samples. In this study, C18 reversed phase column (column temperature of 40 ℃) was used as a stationary phase. Mobile consisted of acetonitrile and formate buffer (1:3, pH 3) with a flow rate of 0.2 ml/min. For the detection enalapril, m/z value was fixed at 377.2. Deproteinating agents (Acetonitrile 100 ㎕, $ZnSO_4$ 10%) were added to human blood sample (i.e., 200 ㎕); Resulting mixture was vortex-mixed and the supernatant collected. Then, an aliquot (5 ㎕) of the supernatant was directly injected on to the HPLC-MS system. Based on the experimental condition, a linear (i.e., r^2=0.9954) correlation between the concentration and the LC-MS response was readily obtained in a concentration range of 3 ~ 225ng of enalapril/ml of human blood using 200 ㎕ blood sample. In addition, variability of the assay was always less than 15 % for precision and accuracy. The limits of detection and quantitation of the method were found to be 1 and 3 ng/ml, respectively. Considering the fact that C_{max} of the drug is approximately 100 ng/ml, the validated HPLC-MS assay has a sufficient sensitivity for the use of pharmacokinetic characterization of enalapril in human subjects (e.g., human bioequivalence trial).

[PE2-2] [10/18/2002 (Fri) 13:30 - 16:30 / Hall C]

The Effect of Nimodipine on the Pharmacokinetics of Cyclosporine in Rabbits

Choi Jun Shik°

College of Pharmacy, Chosun University

The purpose of this study was to report the pharmacokinetic changes of cyclosporine after oral administration of cyclosporine, 10 mg/kg, in rabbits coadministered or pretreated twice per day for 3 days with nimodipine, dose of 5 mg/kg. The area under the plasma concentration-time curve (AUC) of cyclosporine was significantly higher in rabbits pretreated with nimodipine than in control rabbits ($p<0.01$), showing about 149% increased relative bioavailability. The peak plasma concentration (Cmax) , elimination half-life (t 1/2) and MRT of cyclosporine were increased significantly ($p<0.05$) in rabbits pretreated with nimodipine compared with those in control rabbits. This findings could be due to significant reduction of elimination rate constant and total body clearance by pretreated with nimodipine. The effects of nimodipine on the pharmacokinetics of oral cyclosporine were more considerable in rabbits pretreated with nimodipine compared with those in control rabbits. The results suggest that the dosage of cyclosporine should be adjusted when the drug would be coadministered chronically with nimodipine in a clinical situation.

[PE2-3] [10/18/2002 (Fri) 13:30 - 16:30 / Hall C]

Does Agitation Condition Affect the Correlation Between in vitro Permeability of Xenobiotics across Caco-2 Cells and in vivo Bioavailability of the Compounds?

Ho-Jung Yoo°, In-Wha Kim, Soon-Sun Hong, Suk-Jae Chung, Chang-Koo Shim

College of Pharmacy, Seoul National University, Seoul 151-742, Korea

Caco-2 is a cell line derived from the human colon adenocarcinoma and often used as a model for studying intestinal drug absorption. It has been well-known that a strong correlation holds between in vitro permeability across Caco-2 cell monolayers and in vivo bioavailability for various drugs, but the correlation curves varied depending on laboratories. The permeabilities of drugs across Caco-2 cell monolayers have been measured